All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies-Reference-Cited by-同舟云学术

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

Published:2015-05-15 Issue:8 Volume:94 Page:1347-1356
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Sanz Miguel A., ,Montesinos Pau,Kim Haesook T.,Ruiz-Argüelles Guillermo J.,Undurraga María S.,Uriarte María R.,Martínez Lem,Jacomo Rafael H.,Gutiérrez-Aguirre Homero,Melo Raul A. M.,Bittencourt Rosane,Pasquini Ricardo,Pagnano Katia,Fagundes Evandro M.,Vellenga Edo,Holowiecka Alexandra,González-Huerta Ana J.,Fernández Pascual,De la Serna Javier,Brunet Salut,De Lisa Elena,González-Campos José,Ribera José M.,Krsnik Isabel,Ganser Arnold,Berliner Nancy,Ribeiro Raul C.,Lo-Coco Francesco,Löwenberg Bob,Rego Eduardo M.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-015-2393-0.pdf

Reference19 articles.

1. Rego EM, Kim HT, Ruiz-Argüelles GJ et al (2013) Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 121:1935–1943. doi: 10.1182/blood-2012-08-449918

2. Jácomo RH, Melo RAM, Souto FR et al (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92:1431–1432. doi: 10.3324/haematol.10874

3. Sanz MA, Montesinos P, Rayón C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146. doi: 10.1182/blood-2010-01-266007

4. Adès L, Sanz MA, Chevret S et al (2008) Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 111:1078–1084. doi: 10.1182/blood-2007-07-099978

5. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Molecular Diagnostics in Developing Countries;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy;Hematology, Transfusion and Cell Therapy;2024-05

3. Consenso de leucemia mieloide aguda en México;Gaceta Médica de México;2023-03-28

4. Oral Realgar-Indigo Naturalis Formula Treatment for Acute Promyelocytic Leukemia in Children: A Randomized, Control Clinical Trial;Evidence-Based Complementary and Alternative Medicine;2022-07-05

5. Caracterización clínica y citogenética de una cohorte de pacientes con leucemia promielocítica aguda atendidos en un Hospital Universitario en Medellín, Colombia;Medicina y Laboratorio;2022-07-01